

## **Summary of risk management plan for Nintedanib**

This is a summary of the risk management plan (RMP) for nintedanib. The RMP details important risks of nintedanib, how these risks can be minimised, and how more information will be obtained about nintedanib risks and uncertainties (missing information).

Nintedanib's summary of product characteristics (SmPC) and its patient information leaflet (PIL) give essential information to healthcare professionals and patients on how nintedanib should be used.

Important new concerns or changes to the current ones will be included in updates of nintedanib RMP.

### **I. The medicine and what it is used for**

Nintedanib is authorised for, x In adults for the treatment of idiopathic pulmonary

fibrosis (IPF).

- x In adults for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype.
- x In children and adolescents from 6 to 17 years old for the treatment of clinically significant, progressive fibrosing interstitial lung diseases (ILDs).
- x In adults, adolescents and children aged 6 years and older for the treatment of systemic sclerosis associated interstitial lung disease (SSc-ILD).

It contains nintedanib as the active substance, and it is taken via oral route.

### **II. Risks associated with the medicine and activities to minimise or further characterise the risks**

Important risks of nintedanib, together with measures to minimise such risks and the proposed studies for learning more about nintedanib risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- x Specific information, such as warnings, precautions, and advice on correct use, in the PIL and SmPC addressed to patients and healthcare professionals; x Important advice on the medicine's packaging;
- x The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- x The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including Periodic Safety Update Report (PSUR) assessment if PSUR is required by Health Authority, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

If important information that may affect the safe use of nintedanib is not yet available, it is listed under 'missing information' below.

#### ***II.A. List of important risks and missing information***

Important risks of nintedanib are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken.

Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of nintedanib. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

<b>List of Important Risks and Missing Information</b>	
Important identified risk(s)	<input checked="" type="checkbox"/> Drug-induced liver injury (DILI) <input checked="" type="checkbox"/> Bleeding <input checked="" type="checkbox"/> Myocardial infarction <input checked="" type="checkbox"/> Weight decreased in paediatric population
Important potential risk(s)	<input checked="" type="checkbox"/> Venous thromboembolism <input checked="" type="checkbox"/> Arterial thromboembolism excluding myocardial infarction <input checked="" type="checkbox"/> Perforation <input checked="" type="checkbox"/> Hepatic failure <input checked="" type="checkbox"/> Effect on bone development and growth in paediatric population <input checked="" type="checkbox"/> Effect on tooth development disorders in paediatric population
Missing information	<input checked="" type="checkbox"/> Treatment of Scleroderma-associated interstitial lung disease patients with pulmonary hypertension

#### ***II.B. Summary of important risk***

The safety information in the proposed Product Information is aligned to the reference medicinal product.

#### ***II.C. Post-authorisation development plan***

##### ***II.C.1 Studies which are conditions of the marketing authorisation***

There are no studies which are conditions of the marketing authorisation or specific obligation of nintedanib

##### ***II.C.2 Other studies in post-authorisation development plan***

There are no studies required for nintedanib.